MedTrace Logo

Efficacy and Safety of HB-1 for Panic Disorder

NCT06483789 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-12-10

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.

Conditions

  • Panic Disorder
  • Mental Illness

Interventions

DRUG

HB-1

HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

DRUG

Telmisartan Only Product in Oral Dose Form

Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.

DRUG

Verapamil Only Product in Oral Dose Form

Verapamil will be supplied as a single active pharmaceutical ingredient tablet.

DRUG

Placebo

Matched Placebo will be supplied as a tablet.

Sponsors & Collaborators

  • Honeybrains Biotech LLC

    lead INDUSTRY

Principal Investigators

  • Prof. Malcolm Hopwood · Ramsay Clinic Albert Road

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-29
Primary Completion
2027-01-31
Completion
2027-02-28
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06483789 on ClinicalTrials.gov